Enhancing preclinical drug discovery with artificial intelligence.

Journal: Drug discovery today
Published Date:

Abstract

Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.

Authors

  • R S K Vijayan
    Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
  • Jan Kihlberg
    Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden.
  • Jason B Cross
    Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jbcross@mdanderson.org.
  • Vasanthanathan Poongavanam
    Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden. Electronic address: vasanthanathan.poongavanam@kemi.uu.se.